Yu brɔst kansa na HER2-Positiv? Lɛ wi tɔk bɔt dis ditayli!

Yu dɔn ɛva yɛri bɔt bɔdi kansa? Sɔntɛm yu padi ɔ fambul dɔn gɛt am. Fɔ tru, difrɛn kayn bɔdi kansa de. Tide wi go tɔk bɔt wan pan dɛn, we spɛshal ɛn we kin skata kwik kwik wan. Dat na HER2-Positive (HER2-positiv) brɔst kansa . We yu yɛri dis nem, yu go tink se i kɔmplikt smɔl, bɔt nɔ wɔri. Wi go tɔk bɔt am rili simpul wan, di we we yu go ɔndastand.

Wetin na HER2-Positiv (HER2+) Brest Kansa?

fכ simpul wan, HER2-positiv (HER2+) brεst kεnsar na wan kayn kεnsar we de gro kwik εn i kin spre izi wan ausayd di brεst (`invasive`) . we dכkta dεn se yu gεt dis kayn kεnsar, i min se yu kεnsar sεl dεm gεt hכy lεvεl fכ wan spεshal protin we de kכntro di gro εn divεlכpmεnt fכ sεl dεm na yu bכdi – we dεn kכl ``Human Epidermal Growth Factor Receptor 2`` , כ HER2 fכ sכt. dis HER2 protin de lεk ``signal'' we de tεl di sεl dεm fכ gro. We i bɔku, di sɛl dɛn kin sheb kwik kwik wan ɛn dɛn nɔ kin ebul fɔ kɔntrol dɛn, ɛn dis kin mek dɛn gɛt kansa.

Dis kayn brɔst kansa kin pas (metastasize) frɔm di bɔdi to ɔda pat dɛn na yu bɔdi, lɛk di limf no dɛm, di liva, di lɔng dɛm, ɔ ivin yu bren. Bɔt di impɔtant tin na dat, if dɛn no dis kansa kwik kwik wan, bifo i skata to ɔda pat dɛn na di bɔdi, dɔktɔ dɛn kin trit am fayn fayn wan wit di advans tritmɛnt dɛn we de tide. Na dat mek i rili impɔtant fɔ no di pɔsin kwik kwik wan.

Aw kɔmɔn HER2-positiv brɔst kansa?

Di American Cancer Society se insay 2023 nɔmɔ, pas 290,000 uman dɛn go gɛt invasive breast cancer (invasive ductal carcinoma ɛn lobular breast cancer). pan dεm , 15% to 20% na HER2-positiv. Man dɛn kin gɛt bɔdi kansa bak, bɔt HER2-positiv brɔst kansa nɔ kin bɔku pan man dɛn.

Wetin na di sayn dɛm fɔ HER2-positiv brɔst kansa?

lεk bכku kayn brεst kεnsar, dis HER2-positiv sכbtayp sכmtεm dεn n כ de sho klia simptom dεm fכs. Bɔt we di sayn dɛn kin sho, dɛn kin tan lɛk di wan dɛn we dɛn kin si pan bɔdi kansa ɔltɛm. Lɛ wi tek wan luk pan wetin dɛn bi:

• Wan chenj na di sayz, shep, ɔ kɔnto na di bɔdi . Wan brɔst kin fil big pas di ɔda wan, ɔ in shep kin chenj.
• Lump ɔ lump na di brɔst ɔ armpit eria. Dis kin smɔl lɛk pis. If di lump kɔntinyu afta yu menstrual saykl dɔn, yu fɔ wɔri.
• Wan chenj na di we aw di skin na di bɔdi ɔ di nipple de luk ɔ fil . Di skin kin rɔf, i kin gɛt smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl. Sɔntɛnde, di skin kin rɛd ɔ dak pas aw i kin bi.
• Fɔ fil wan say we at ɔnda di skin, lɛk mabul .
• Blɔd ɔ klia wata we de kɔmɔt na di nipple.

Imajin, yu padi, mek wi kol am "Sunita". Wan de, we Sunita bin de was, i notis wan smɔl chenj na in bɔdi. I bin tan lɛk se na smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl. Fɔs, i nɔ bin pe atɛnshɔn tumɔs to am, i bin de tink se, "I go jɔs go." Bɔt afta sɔm wiks, i bin stil de. Leta, we i sho am to dɔktɔ, i kam fɔ no se na sayn fɔ gɛt kansa na in bɔdi. So, if yu notis ɛni chenj we nɔ kɔmɔn na yu bɔdi, i rili impɔtant fɔ go to dɔktɔ we yu nɔ fɔ pe atɛnshɔn to am.

Wetin kin mek pɔsin gɛt HER2-positiv brɔst kansa?

HER2-positiv brεst kεnsar de kכz bay wan mכtεshכn insay wan jin we dεn kכl HER2. dis HER2 jin de prodyuz di HER2 protin we wi bin tכk bכt fכs. dis HER2 protin dεm (dεn kכl dεm bak `rεsεptor`) dεn nכmal fכ de na di sεf fכ כl di brεst sεl dεm.

כnda nכmal sεl dεm, dεn HER2 protin dεm ya de kכntro di brεst sεl dεm we de gro εn ripa, we de mek sכh se nyu sεl dεm de divayd insay inof nכmba fכ tek ples fכ di sεl dεm we dεn dכn pwεl כ we de day.

כltu, we dεn chenj di HER2 jin, i de mek tu mכch kכpi dεm fכ insεf. we di HER2 jin dεn ova εksprεs, i de mek tu mכch pan di HER2 protin bak. we di HER2 protin tu bכku, di brεst sεl dεm de sheb kwik kwik wan εn de gro we dεn nכ de kכntro, we de bi kεnsar tכmכro.

Wetin na di risk factor dɛm fɔ dis?

lεk brεst kεnsar, di risk fכ HER2-positiv brεst kεnsar na di sem lεk fכ rεgulεr brεst kεnsar. Yu kin gɛt bɔdi kansa ilɛksɛf yu gɛt dɛn tin ya we kin mek yu gɛt kansa ɔ yu nɔ gɛt am. Bɔt dɛn tin ya kin mek yu gɛt mɔ prɔblɛm:

• Fɔ gɛt wan jɛnɛtik muteshɔn we dɛn gɛt frɔm dɛn mama ɛn papa . fכ egzampl, wan mכtεshכn na di jin dεm we dεn kכl BRCA1 כ BRCA2.
• Bikɔs i bin dɔn gɛt bɔdi kansa bifo.
• fכ gεt כda kכndyushכn dεm we de fכm di brεst lεk `atypical ductal hyperplasia`.
• di saykl we di mεnstral de bigin fכ bifo pas aw i nכmal.
• Menopause kin apin leta pas di nɔmal ej.
• Fɔ tek ɔmon riplesmɛnt tɛrapi.
• Fɔ drink pas wan rɔm fɔ wan de.
• We dɛn dɔn du redyushɔn tɛrapi fɔ sɔm kɔndishɔn dɛn lɛk limfoma (kansa na di limfatik sistɛm).

Wetin na di kɔmplikɛshɔn dɛm fɔ HER2-positiv brɛst kansa?

HER2-Pozitiv brεst kεnsar kin spre to כda pat dεm na di bכdi, כ ‘mεtastasize’. Na lɛk af pan pipul dɛm wae gɛt dis kayn brɔst kansa, di kansa dɔn ɔlrɛdi spre to ɔda pat dɛm na dɛn bɔdi, mɔ na di bren, bay di tɛm we dɛn no se dɛn gɛt am. Brest kansa we dɔn spre to di bren (‘metastatic breast cancer to your brain’) kin mek yu layf de pan denja. Na dat mek i impɔtant fɔ no am kwik kwik wan ɛn fɔ trit am kwik kwik wan.

Aw dɛn kin no se pɔsin gɛt HER2 we gɛt bɔdi kansa?

Dɔktɔ dɛn kin yuz mɔ brɔst bayɔpsi fɔ no ɔl di bɔdi kansa dɛn. Dis min se yu fɔ tek wan smɔl pat pan di tisu frɔm wan say we yu tink se na di bɔdi ɛn chɛk am ɔnda maykroskɔp.

if di brεst bayopsi kכnfכm se kansa de, mεdikal patכlayz (dכkta we spεshal fכ no sik dεm) go du spεshal tεst fכ si if di brεst tisu sεl dεm gεt di HER2 protin. Tu men kayn tɛst de fɔ dis:

1. Immunohistochemistry (IHC): dis tεst de alaw di patכlayz dεm fכ luk fכ di HER2 protin insay brεst kεnsar sεl dεm. dis tεst de yuz spεshal day (immunostaining) fכ chεk di lεvεl fכ HER2 protin insay di kεnsar sεl dεm.

2. Fluorescence in situ hybridization (FISH): sכmtεm dεn kin yuz dis FISH tεst fכ kכnfכm di risכlt fכ di IHC tεst. dis tεst kin no if εkstra kכpi dεm de fכ di HER2 jin.

Afta dɛn tɛst ya, dɔktɔ dɛn kin klas di kansa mɔ. Dɛn de yuz wan `skɔring sistɛm`. dis de luk aw di lεvεl fכ di HER2 protin de na di brεst tisu sεmpl, εn כlso כl di kεnsar sεl dεm de. Tink bɔt am dis we:

• if di tεst sho se di HER2 protin lεvεl lכw, dεn go skכ am 0 כ 1+ . Dɔn di patɔlɔjis go se i nɔ gɛt HER2 .
• if kansa sεl dεm de εn di protin lεvεl mכdarεt, yu kin gεt skכl 2+ . Dɔn di patɔlɔjis go kɔnfɔm bak di `FISH` tɛst we wi bin dɔn tɔk bɔt.
• if bכku kεnsar sεl dεm de εn di protin lεvεl rili hכy, yu gεt skכl 3+ . Na da tɛm de di patɔlɔjis se na HER2 pɔsitiv .

dis skכring sistεm de disayd εksakכt if yu na HER2-positiv כ HER2-nεgεtiv.

Wetin na di tritmɛnt dɛm fɔ HER2-positiv brɔst kansa?

biכs dis na `invasive` tכp fכ brεst kεnsar, di tritmεnt opshכn dεm de ditarεmin bay plεnti tin dεm, lεk di stej fכ di kεnsar εn HER2 stetכs. Yu kin yuz dɛn tritmɛnt ya:

• Tɛrapi we dɛn de tɔk to:Dis na di mכst spεsifi k tritmεnt fכ HER2-positiv kεnsar. i involv fכ gi dכg dεm we de tכk to di HER2 protin εn kil di kεnsar sεl dεm. Bɔku men kayn tritmɛnt de ɔnda dis:
• monoklonal antibodi tεrapi: dεn ya de biεn di HER2 protin εn stכp di kεnsar sεl dεm fכ gro.
• Tyrosine kinase inhibitor therapy: Dɛn drɔgs ya de go insay di kansa sɛl dɛn ɛn blɔk di signal path dɛn we de ɛp di sɛl dɛn fɔ gro.
• Antibodi-drug conjugates (ADCs): Dis na wan we we rili advans. insay dis, wan anti-kansa dכg de atak wan antibodi we de luk fכ kεnsar sεl dεm. Dɔn dis kɔmpawnd kin go dairekt to di kansa sɛl dɛn ɛn pul di mɛrɛsin, ɛn dis kin mek di sɛl dɛn we gɛt wɛlbɔdi nɔ pwɛl bɛtɛ.
• Kimotɛrapi: Dɛn kin gi kimotɛrapi bifo dɛn du di ɔpreshɔn fɔ mek di tumbu smɔl (neoadjuvant therapy) ɔ fɔ kil ɛni kansa sɛl we lɛf afta dɛn du di ɔpreshɔn (adjuvant therapy). Sɔntɛnde, dɛn kin gi kemotɛrapi togɛda wit di tritmɛnt we dɛn dɔn tɔk bɔt.

apat frכm dis, dipכnt pan di stej we di kεnsar de, dεn kin du tin dεm lεk `sכjεri`, `rεdyushכn tεrapi`, כ `hכmon tεrapi` bak.

Wetin na di sayd ɛfɛkt dɛm we di tritmɛnt dɛm kin gɛt?

Di sayd ɛfɛkt kin difrɛn difrɛn wan bay di tritmɛnt. If yu de gɛt tritmɛnt, tɔk to yu dɔktɔ bɔt aw de tritmɛnt go afɛkt yu ɛn aw i go afɛkt yu ɛvride layf. Dɔn bak, aks yu dɔktɔ bɔt aw fɔ kia fɔ yu bɔdi we nɔ de mek yu fil fayn . Palliative care na savis wae de ɛp yu fɔ manej di simptom dɛm fɔ kansa ɛn di sayd ɛfɛkt dɛm wae de kam wit tritmɛnt ɛn mek yu fil fayn as yu kin du di tritmɛnt. I nɔr de jɔs fɔ pipul dɛm wae nɔr kin ebul fɔ mɛn kansa, bɔt kin ɛp ɛnibɔdi wae de du tritmɛnt.

Dɛn tritmɛnt ya kin mɛn HER2-positiv brɔst kansa kɔmplit wan?

We dɔktɔ dɛn se dɛn "kɔr" kansa, dɛn go mɔs min se dɛn bin put di kansa na rɛmishɔn fɔ lɔng lɔng tɛm wit tritmɛnt. Rimishɔn min se yu nɔ gɛt ɛni sayn fɔ di kansa ɛn yu nɔ go ebul fɔ fɛn ɛni kansa pan tɛst. Pɔsin we dɛn no se gɛt HER2-positiv brɔst kansa, we dɛn trit, ɛn liv fɔ fayv ia, dɛn kin tek am se i dɔn "krɔs."

Akɔdin to di US Nashɔnal Kɛnsa Instityut (NCI), pas 90% pan di pipul dɛm we dɛn no se gɛt HER2-positiv brɔst kansa stil de alayv afta fayv ia. Dɛn kin tek dɛn se dɛn dɔn wɛl frɔm dɛn kansa. כltu, HER2-positiv kεnsar kin kam bak εn spre to כda pat dεm na di bכdi. So, i impɔtant fɔ kɔntinyu fɔ go fɔ mek dɛn chɛk yu fɔ mɛn yu.

Wetin na di rεt we de liv fכ HER2-positiv brεst kεnsar?

di chans fכ liv HER2-positiv brεst kεnsar de difrεn bak dipכnt if di kεnsar na כmon rεsεpכta-positiv (HR+) כ כ mon rεsεpכta-nεgεtiv (HR-) . .

Yu tink se dɛn kin ebul fɔ protɛkt HER2-positiv brɔst kansa?

I go mɔs bi se nɔto so. Pan ɔl we tin dɛn de we yu kin du fɔ ridyus di risk fɔ gɛt bɔdi kansa, HER2-positiv brɔst kansa kin kɔmɔt frɔm wan muteshon na di HER2 jin we kin mek kansa sɛl dɛn fɔm. Risach pipul dɛn stil de stɔdi wetin mek dis kin apin, so dɛn nɔ ebul yet fɔ tɔk klia wan wetin dɛn kin du fɔ mek dɛn nɔ gɛt HER2-positiv kansa.

Bɔt yu kin du dɛn tin ya fɔ ridyus yu risk fɔ gɛt bɔdi kansa in jɔnaral:

• Tek kia ɔf yu bɔdi wɛlbɔdi. Du yu brɔst sɛlf-ɛgzam ɔltɛm, ɛn tek mammogram di ej ɛn di intaval dɛn we yu dɔktɔ se. Yu fɔ no bɔt ɛni chenj we de na yu bɔdi. Dis we ya, dɛn kin no kansa kwik kwik wan ɛn trit am izi wan.
• Mek yu gɛt wɛlbɔdi wet. Dis fɔ bi wet we go mek yu fil fayn. Aks yu dɔktɔ fɔ advays yu bɔt aw fɔ mek yu gɛt wɛlbɔdi.
• It tin dɛn we go mek yu gɛt wɛlbɔdi. Sɔm stɔdi dɛn dɔn sho se if pɔsin it bɔku vɛjitebul, frut, tin dɛn we dɛn mek wit milk we gɛt kalsiɔm, ɛn tin dɛn we nɔ gɛt bɔdi, dat kin mek i nɔ gɛt bɔku kansa na in bɔdi. I fayn bak fɔ stɔp rɛd ɛn prɔses mit.
• Bi aktif. Stɔdi dɛn dɔn sho se we yu de du yu bɔdi ɔltɛm, dat kin mek yu nɔ gɛt kansa na yu bɔdi. Ivin fɔ jɔs waka fɔ 30 minit insay di de, i fayn.
• Nɔ drink rɔm. Risach dɔn sho se sɔntin gɛt sɔntin fɔ du wit bɔdi kansa ɛn rɔm. Di American Medical Association se uman dɛn fɔ stɔp fɔ drink wan rɔm fɔ wan de.

Aw a kin kia fɔ misɛf?

Fɔ liv wit brɔst kansa min fɔ liv wit di sayn dɛm fɔ kansa, di tritmɛnt dɛm, ɛn di sayd ɛfɛkt dɛm we di tritmɛnt kin gɛt. Ɛn, sɔntɛnde, yu kin gɛt fɔ liv wit di we aw yu nɔ no wetin go apin tumara bambay. Sɔntɛnde, yu kin fil bad ɛn yu at kin fil bad. If yu fil da we de, tink bɔt dɛn advays ya fɔ kia fɔ yusɛf:

• Gɛt inof rɛst.Brest kansa ɛn tritmɛnt kin rili taya. Mɛmba fɔ rɛst ɛnitɛm we yu fil want, nɔto jɔs we yu gɛt tɛm.
• It gud gud wan. Di tritmɛnt kin mek yu nɔ want fɔ it, bɔt if yu it tin dɛn we gɛt bɔku frut, vɛjitebul, tin dɛn we nɔ gɛt bɔdi, ɛn tin dɛn we gɛt wɛlbɔdi, dat go ɛp yu fɔ strɔng we yu de trit yu.
• Manej yu strɛs. Kansa na big tin we kin mek pɔsin strɛs. Ɛksesaiz kin ɛp fɔ du dis. Fɔ waka ɔltɛm ɛn tek pat pan ɛksɛsayz program dɛn lɛk yoga fayn.
• Gɛt sɔpɔt. Yu na pɔsin we dɔn sev frɔm bɔdi kansa, ɛn dat kin bigin di de we dɛn no se yu gɛt am. Aks yu dɔktɔ bɔt di program dɛn fɔ mek pɔsin nɔ gɛt kansa . Dɛn tin ya kin ɛp yu fɔ win di prɔblɛm dɛn we yu kin gɛt we yu de liv wit bɔdi kansa. We yu de tɔk to yu fambul ɛn padi dɛn, na fayn we bak fɔ sɔpɔt yusɛf.

Ustɛm a fɔ go to dɔktɔ?

Yu go nid fɔ go to yu dɔktɔ ɔltɛm we yu de du tritmɛnt. Bɔt if yu notis ɛni nyu chenj na yu bɔdi ɔ yu bɔdi we kin bi sayn fɔ se yu HER2-positiv kansa dɔn skata, tɛl yu dɔktɔ wantɛm wantɛm. Fɔ ɛgzampul, if brɔst kansa dɔn skata to di lɔng, yu kin gɛt sɔm sayn dɛn lɛk we yu de fil pen na yu chɛst, yu kin gɛt infɛkshɔn na yu chɛst ɔltɛm, i nɔ kin izi fɔ yu fɔ blo, ɔ yu kin kɔf blɔd.

Ustɛm a fɔ go na di imejensi rum?

If yu bɔdi de ansa to kansa tritmɛnt wɔs pas aw yu bin de tink, yu fɔ go na di imejensi rum. Fɔ ɛgzampul, if yu nɔ gɛt wata bad bad wan bikɔs yu de vɔmit ɔltɛm, go na ɔspitul wantɛm wantɛm.

Us kwɛstyɔn dɛn a fɔ aks mi dɔktɔ?

If yu tɛst sho se yu gɛt HER2-positiv brɔst kansa, yu kin aks yu dɔktɔ kwɛstyɔn dɛn lɛk:

• Wetin na mi HER2 stetɔs ɛksaktɔli ? (i.e. wetin na mi IHC/FISH skɔ?)
• Wetin na mi ɔmon riseptɔ stetɔs ? (HR+ ɔ HR-?)
• aw dεn HER2 εn כmon rεsεpכta stetכs dεm de afekt mi prכgnosis (i.e., di prכgnosis εn di fכs kכs fכ di sik)?
• Us tritmɛnt dɛn yu kin kɔmɛnt fɔ mi? Wetin du?
• A fɔ tink bɔt fɔ tek pat pan klinik trial fɔ trit HER2-positiv brɔst kansa?

Brekthrough in kansa tritmɛnt nɔ kin bɔku. na dat mek di wan dεm we de du risach pan kεnsar bin rili gladi we stכdi dεm sho se di mכtεshכn dεm na di HER2 jin de mek di sεl dεm divayd kwik pas nכmal. kwik kwik wan dεn bin fכnshכn wan link bitwin HER2 jin mכtεshכn εn sכm kayn brεst kεnsar we de gro fast fast. Frɔm de, dɛn mek tritmɛnt dɛn we go ebul fɔ trit di fɔs stej HER2-positiv brɔst kansa fayn fayn wan. Naw, di wan dɛn we de stɔdi bɔt dis de pe atɛnshɔn fɔ fɛn mɔ tritmɛnt dɛn we go wok fayn ɛn we go mek kansa slo ɔ stɔp fɔ prɛd. Klinik trial na di say we dɛn nyu tin ya we dɛn dɔn fɛn kin apin. If yu gɛt mɛtastas (‘mɛtastatik’) HER2-positiv brɔst kansa, tɔk to yu dɔktɔ bɔt fɔ tek pat pan klinik trial. Dɛn kin ɛp yu.

Fɔ dɔn, mɛsej we yu kin kɛr go na os

HER2-positiv brɔst kansa na siriɔs, fast-spred kayn kansa. Bɔt wit di kɔrɛkt ɛn kwik fɔ no ɛn advans tritmɛnt opshɔn dɛm, naw i pɔsibul fɔ kɔntrol ɛn mɛn dis sik fayn fayn wan.

• Ɔltɛm pe atɛnshɔn to yu bɔdi, mɔ yu bɔdi. If yu notis ɛni chenj we nɔ kɔmɔn, nɔ ignore am ɛn go to dɔktɔ wantɛm wantɛm.
• Fɔ fala di tɛst ɛn tritmɛnt dɛn we yu dɔktɔ tɛl yu fɔ du. Nɔr frayd fɔ tɔk to yu dɔktɔ bɔt ɛni kwɛstyɔn ɔr tin wae de mɔna yu.
• I rili impɔtant fɔ mek yu kɔntinyu fɔ tink gud wan. Nɔto yu wan de. Famili, padi, dɔktɔ, ɛn advays savis de fɔ ɛp yu.

Wi op se dis infɔmeshɔn go fayn fɔ yu. Stay wit wɛlbɔdi!

` Brest kansa, HER2-Positiv, kansa simptom, kansa tritmεnt, uman dεm hεlth, jεnεtik mכtεshכn, mammogram